Biosimilars offer the promise of cutting edge treatments, but possibly at lower costs. With society pushing for therapies leading to a cure, can this new class of drugs help answer some of cancer’s most challenging problems? How will doctors and patients respond to the increased availability of biosimilars in the US? What has been the general reception regarding clinical use and safety? And how do we navigate the regulatory landscape as we look further afield?
The Atlantic gathered leading experts, oncologists and patients to explore the future of biosimilars in cancer treatment.